Your browser doesn't support javascript.
loading
Sequelae and post-thrombotic syndrome after venous thromboembolism in acute lymphoblastic leukemia survivors treated on the NOPHO ALL2008 protocol.
Dam, Merete; Lynggaard, Line Stensig; Jónsson, Ólafur G; Saulyte Trakymiene, Sonata; Palk, Katrin; Jarvis, Kirsten; Andrés-Jensen, Liv; Tuckuviene, Ruta; Albertsen, Birgitte Klug.
Afiliação
  • Dam M; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Lynggaard LS; Department of Hematology, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Jónsson ÓG; National University Hospital of Iceland, Reykjavik, Iceland.
  • Saulyte Trakymiene S; Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Palk K; The North Estonia Medical Centre, Tallinn, Estonia.
  • Jarvis K; Department of Paediatric Haematology and Oncology, Oslo University Hospital, Oslo, Norway.
  • Andrés-Jensen L; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Tuckuviene R; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Albertsen BK; Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, and Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Pediatr Blood Cancer ; 71(6): e30937, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38480517
ABSTRACT
The treatment of acute lymphoblastic leukemia (ALL) is frequently complicated by toxicity, including venous thromboembolism (VTE) affecting roughly 8% of patients. VTE can lead to post-thrombotic syndrome (PTS), a group of signs and symptoms developed as a complication to deep venous thrombosis (DVT), imposing risk of permanent disability and reduced quality of life (QoL). PTS prevalence ranges from 0% to 70%, reflecting very heterogenous cohorts and assessment tools. We aimed to estimate sequelae, including PTS and QoL in children and adults (<45 years old) who had a DVT during ALL treatment. PTS and QoL scores were obtained through use of Villalta and Modified Villalta Scale, PedsQL, and Short Form-36 questionnaires. The cohort comprised 20 children (<18 years) and seven adults (median age 12.9 years, range 2-44 years) at the time of DVT diagnosis. In total, 25 ALL survivors underwent PTS examination. The examination took place when survivors were 7-48 years (median age 20.3 years, median follow-up time 6.8 years). QoL was assessed correlating cases with three matching ALL survivors without VTE. Two adults (15.4%) showed mild or moderate PTS. Eight children (66.7%) were diagnosed with mild PTS, while three cases had collaterals as sole symptoms. Pain or symptoms affecting daily life were reported by 16%. No difference in QoL was found (p = .9). This study underscores the need for comprehensive population-based investigations with validation of PTS instruments in ALL survivors.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article